- Adamis Pharmaceuticals Corporation ADMP has initiated dosing in the Phase 2/3 trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection.
- The trial is designed to enroll 248 patients.
- Related: Immunology Journal Publishes Data For Adamis' COVID-19 Candidate
- An interim analysis by the data and safety monitoring board (DSMB) will examine safety and markers of systemic inflammation during a Stage 1 interim analysis.
- Based on the DSMB analysis, the Phase 3 portion of the trial designed to enroll 198 patients may begin, with a second interim analysis planned after the enrollment of 124 patients.
- Also Read: NIH Sees Promise in Tempol for COVID-19
- Price Action: ADMP stock is up 2.70% at $1.14 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPhase 2 Trial
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
